Burning Rock Biotech Ltd (BRB) is a biotechnology company that focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. The company offers core products such as OncoCompass Plus targeted and lmmuno therapy drug screening, OncoCompass target reliable and evidence-based ctDNA testing, OverC multi-cancer detection blood test which is a revolution in multi-cancer early detection and others. It provides cancer genomic solutions for pharmaceutical companies from biomarker discovery to commercialization. The company operates in China and the US. BRB is headquartered in Guangzhou, Guangdong, China.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Burning Rock Biotech Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Burning Rock Biotech Ltd Company Overview
- Burning Rock Biotech Ltd Company Snapshot
- Burning Rock Biotech Ltd Pipeline Products and Ongoing Clinical Trials Overview
- Burning Rock Biotech Ltd - Pipeline Analysis Overview
- Burning Rock Biotech Ltd - Key Facts
- Burning Rock Biotech Ltd - Major Products and Services
- Burning Rock Biotech Ltd Pipeline Products by Development Stage
- Burning Rock Biotech Ltd Ongoing Clinical Trials by Trial Status
- Burning Rock Biotech Ltd Pipeline Products Overview
- 22-Cancer Test
- 22-Cancer Test Product Overview
- CDx Assay - ABSK091
- CDx Assay - ABSK091 Product Overview
- Companion Diagnostic Assay - Prostate Cancer
- Companion Diagnostic Assay - Prostate Cancer Product Overview
- Next-Generation Sequencing Based Companion Diagnostic Assay
- Next-Generation Sequencing Based Companion Diagnostic Assay Product Overview
- OncoCompass Target CDx Test - Tepotinib
- OncoCompass Target CDx Test - Tepotinib Product Overview
- OverC Multi-Cancer Detection Blood Test Kit
- OverC Multi-Cancer Detection Blood Test Kit Product Overview
- OverC Multi-Cancer Detection Blood Test Kit Clinical Trial
- Burning Rock Biotech Ltd - Key Competitors
- Burning Rock Biotech Ltd - Key Employees
- Burning Rock Biotech Ltd - Locations And Subsidiaries
- Head Office
- Recent Developments
- Burning Rock Biotech Ltd, Recent Developments
- Dec 19, 2023: Burning Rock Announces Results of 2023 Annual General Meeting
- Nov 20, 2023: Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023
- Oct 15, 2023: Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test
- Sep 07, 2023: Burning Rock’s Minimal Residual Disease (MRD) Product Supports Advancement in Early-Stage Non-small Cell Lung Cancer Treatment, With Results Published in the Cancer Cell
- Jun 08, 2023: Published in the New England Journal of Medicine
- Jun 08, 2023: Burning Rock’s Precision Oncology Diagnostics Product Supports Advancement in Late-Stage Breast Cancer Treatment, With Results Published in the New England Journal of Medicine
- Apr 27, 2023: Burning Rock Provides First Quarter 2023 Business Updates and Schedules Earnings Release on May 30, 2023
- Sep 08, 2022: Burning Rock Announces Results of 2022 Annual General Meeting
- Aug 03, 2022: Burning Rock Announces 2022 Annual General Meeting to be Held on September 8, 2022
- Jun 30, 2022: Burning Rock announces the launch of China’s first prospective interventional validation study on multi-cancer early detection - the PREVENT Study
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Burning Rock Biotech Ltd Pipeline Products and Ongoing Clinical Trials Overview
- Burning Rock Biotech Ltd Pipeline Products by Equipment Type
- Burning Rock Biotech Ltd Pipeline Products by Indication
- Burning Rock Biotech Ltd Ongoing Clinical Trials by Trial Status
- Burning Rock Biotech Ltd, Key Facts
- Burning Rock Biotech Ltd, Major Products and Services
- Burning Rock Biotech Ltd Number of Pipeline Products by Development Stage
- Burning Rock Biotech Ltd Pipeline Products Summary by Development Stage
- Burning Rock Biotech Ltd Ongoing Clinical Trials by Trial Status
- Burning Rock Biotech Ltd Ongoing Clinical Trials Summary
- 22-Cancer Test - Product Status
- 22-Cancer Test - Product Description
- CDx Assay - ABSK091 - Product Status
- CDx Assay - ABSK091 - Product Description
- Companion Diagnostic Assay - Prostate Cancer - Product Status
- Companion Diagnostic Assay - Prostate Cancer - Product Description
- Next-Generation Sequencing Based Companion Diagnostic Assay - Product Status
- Next-Generation Sequencing Based Companion Diagnostic Assay - Product Description
- OncoCompass Target CDx Test - Tepotinib - Product Status
- OncoCompass Target CDx Test - Tepotinib - Product Description
- OverC Multi-Cancer Detection Blood Test Kit - Product Status
- OverC Multi-Cancer Detection Blood Test Kit - Product Description
- OverC Multi-Cancer Detection Blood Test Kit - A Prospective Multi-cancer Early-detection and Interventional Study in Asymptomatic Individuals: PREVENT
- OverC Multi-Cancer Detection Blood Test Kit - A Prospective, Multicenter Study on Development and Validation of the Performance of a cfDNA Methylation-based Model for Early Cancer Detection (Pan-cancer Early Detection project, PREDICT Study)
- OverC Multi-Cancer Detection Blood Test Kit - Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Myeloma: a Proof of Concept Study
- OverC Multi-Cancer Detection Blood Test Kit - Assessment of Early Detection Based on Liquid Biopsy in Intracranial Tumors: a Prospective Observational Study
- OverC Multi-Cancer Detection Blood Test Kit - Burning Rock Pan-cancer Early Detection Project (PREDICT): A Prospective, Multicenter Study to Develop and Validate the Performance of a Cfdna Methylation Based Model on Early Cancer Detection
- OverC Multi-Cancer Detection Blood Test Kit - Early Detection of Primary Liver Cancer Based on cfDNA Methylation: A Multi-Center Case-Control Study (PRIMe-liver)
- OverC Multi-Cancer Detection Blood Test Kit - Gynecological Malignancies Earlystage Detection by Multi-omics Based Liquid Biopsy in Peripheral Blood: a Prospective, Extended Validation Study
- OverC Multi-Cancer Detection Blood Test Kit - Pan-cancer Early-stage Detection by Liquid Biopsy in Peripheral Blood: A Multi-center, Prospective Observational Study
- Burning Rock Biotech Ltd, Key Employees
- Glossary
- Burning Rock Biotech Ltd Pipeline Products by Equipment Type
- Burning Rock Biotech Ltd Pipeline Products by Development Stage
- Burning Rock Biotech Ltd Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Roche Shanghai Co Ltd
- Creative Biosciences (Guangzhou) Co Ltd
- AmoyDx (Canada) Ltd
- BGI Genomics Co Ltd
- Zero Krypton Technology (Beijing) Co Ltd
- Geneseeq Technology Inc
- Novogene Co Ltd
- Illumina (China) Scientific Co Ltd
